使用炎症性肠病患者肠道类器官在犬肠道芯片中的三维形态发生
February 9th, 2024
3.4K views
犬肠道类器官和Gut-on-a-Chip微流控系统的集成为人类肠道疾病提供了相关的转化模型。提出的协议允许肠道的 3D 形态发生和动态 体外 建模，有助于开发针对狗和人类肠道疾病的有效治疗方法。
我们的研究目标是创造一种使用与人类相似的动物（特别是狗）的肠道细胞培养 3D 结构的方法。肠道细胞形态发生主要通过实验动物模型进行研究，这些模型成本高昂、耗时且不能准确代表人类发育过程。此外，传统的静态 2D 细胞培养模型缺乏模拟 3D abSerial 结构的复杂空间组织的能力。
将来自肠道类器官的单个细胞附着在ECM涂层的PDMS表面上是一个重大挑战。这是应对这一挑战的关键一步，既要确保通过表面活化获得均匀的ECM涂层，又要使其在一夜之间干燥。患者来源的犬类类器官技术与体外 3D 形态发生相结合，为开展慢性多因素疾病转化研究提供了一条有前途的途径，与"同一个健康倡议"保持一致。
犬IBD的协议，在芯片上，为比较医学提供了一个可复制的模型，能够研究肠道形态发生，宿主-微生物组相互作用，感染，药物和益生菌筛选，并具有跨物种适用性。
概述
本研究聚焦于犬肠道类器官与芯片上肠道微流控系统的整合，为人类肠道疾病提供了一个相关的模型。所开发的协议促进了肠道的三维形态发生和动态体外建模，有助于犬类和人类肠道疾病治疗的进步。
关键研究组成部分
科学领域
- 神经科学
- 比较医学
- 微流控技术
背景
- 肠道细胞形态发生对于理解肠道健康至关重要。
- 传统模型往往无法准确代表人类过程。
- 犬类模型为人类肠道疾病提供了更接近的近似。
- One Health倡议强调了人类和动物健康的相互关联性。
研究目的
- 开发一个可重复的模型以研究肠道形态发生。
- 探索宿主-微生物组互动及其对健康的影响。
- 在比较背景下促进药物和益生菌筛选。
使用的方法
- 用ECM涂层准备芯片上肠道装置。
- 将犬类肠道类器官种植到微流控系统中。
- 应用连续流动和周期性应变以模拟生理条件。
- 使用免疫荧光染色评估三维结构和屏障功能。
主要结果
- 在微流控系统中成功建立了三维形态发生。
- 观察到绒毛状结构和功能性肠道屏障。
- 展示了进行肠道疾病比较研究的潜力。
- 验证了该模型用于未来转化研究的有效性。
结论
- 芯片上肠道模型是研究肠道健康的有前景的工具。
- 犬类类器官的整合增强了研究结果的相关性。
- 这种方法与One Health观点一致，有利于人类和动物的健康。
常见问题
使用犬类肠道类器官的意义是什么？
犬类肠道类器官提供了一个更接近人类肠道疾病的模型，促进了更相关的研究。
芯片上肠道系统如何工作？
芯片上肠道系统模仿肠道环境，允许进行细胞相互作用和形态发生的动态研究。
这项研究的应用是什么？
这项研究可应用于药物测试、了解肠道疾病和探索微生物组相互作用。
本研究面临了哪些挑战？
挑战包括实现均匀的ECM涂层和确保微流控系统中的细胞适当附着。
这项研究如何为One Health倡议做出贡献？
它通过使用犬类模型研究人类疾病，强调了人类和动物健康的相互关联性。
这项研究暗示了哪些未来的研究方向？
未来的研究可以探索更复杂的疾病模型和各种治疗对肠道健康的影响。
Executive Industry Relevance
Integrating canine intestinal organoids with microfluidic Gut-on-a-Chip systems enables physiologically relevant, dynamic in vitro models for intestinal disease research. This approach addresses the limitations of traditional static and animal models by providing a platform for predictive, translational studies in both veterinary and human contexts. The resulting models support cross-species insights, enhancing target validation and de-risking early-stage discovery for intestinal therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of disease-relevant pathways using primary cells from spontaneous canine IBD cases.
- Supports functional target validation by recapitulating 3D intestinal morphogenesis and barrier function.
- Facilitates mechanistic de-risking through direct observation of host-microbiome and epithelial interactions.
Screening & Assay Development
- Provides a standardized, reproducible platform for drug and probiotic screening in a dynamic gut environment.
- Delivers quantitative outputs such as TEER measurements for barrier integrity assessment.
- Prepares validated biological systems for scalable compound evaluation and cross-species comparison.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by modeling spontaneous disease in a One Health framework.
- Enables continuity from discovery through preclinical validation using physiologically relevant canine models.
- Supports risk-adjusted advancement decisions by bridging veterinary and human intestinal disease research.
Pipeline & Workflow Integration
This Gut-on-a-Chip protocol positions itself at the intersection of early discovery, lead identification, and preclinical research for intestinal disease programs.
- Discovery Biology: Advances hypothesis testing and pathway clarification in disease-relevant systems.
- Screening: Establishes assay readiness and reproducibility for functional and barrier assays.
- Analytics: Enables quantitative readouts such as TEER and immunofluorescent structural analysis.
- Translational Research: Provides a cross-species platform for biomarker alignment and comparative studies.
- Enterprise Reuse: Offers a reusable microfluidic system adaptable to various intestinal disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in intestinal disease modeling.
- Operational Value: Delivers standardized, scalable, and reproducible workflows for organoid-based assays.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by enabling early de-risking.
- Portfolio Impact: Supports risk-adjusted prioritization and cross-species advancement of intestinal therapeutics.
Implementation Considerations
- Requires expertise in organoid culture, microfluidics, and canine tissue handling.
- Demands access to ECM-coating, microfluidic instrumentation, and TEER measurement infrastructure.
- Necessitates cross-team standardization for reproducible ECM coating and cell seeding.
- Adaptation across species or disease models may require protocol optimization.
- Limitations include technical challenges in uniform cell attachment and maintaining 3D morphogenesis.
Biopharma FAQs
Why does null hypothesis testing matter for canine Gut-on-a-Chip target validation?
Null hypothesis testing enables objective evaluation of whether observed 3D morphogenesis and barrier function in the canine Gut-on-a-Chip are statistically significant compared to controls. This supports robust target validation by distinguishing true biological effects from background variability. Such rigor is essential for advancing candidates in cross-species intestinal disease research.
How does independent variable isolation fit the microfluidic organoid workflow?
Isolating variables such as flow rate, ECM composition, and cyclic strain within the Gut-on-a-Chip system allows precise attribution of effects on epithelial morphogenesis and barrier integrity. This controlled environment strengthens mechanistic insights and informs rational assay development for discovery-stage programs.
What do quantitative TEER measurements enable in this protocol?
Quantitative TEER measurements provide real-time assessment of intestinal barrier function, enabling comparison of experimental conditions and monitoring of epithelial integrity. These outputs support data-driven decisions in screening and validation workflows for intestinal therapeutics.
Why are replication requirements critical for cross-functional Gut-on-a-Chip studies?
Replication ensures that observed 3D morphogenesis and functional readouts are reproducible across experiments and teams, supporting cross-functional collaboration. This reliability is vital for integrating Gut-on-a-Chip data into broader R&D pipelines and for regulatory or translational alignment.
Which statistical analysis capabilities are required before Gut-on-a-Chip implementation?
Robust statistical analysis is needed to interpret TEER values, morphogenesis frequency, and immunofluorescent data, ensuring that findings are significant and actionable. Teams must establish analytical pipelines capable of handling quantitative outputs and supporting hypothesis-driven research decisions.
